Sarcopenia plus metabolic syndrome and cognitive trajectories in Chinese adults 45+
In a Chinese cohort aged 45+, people with both sarcopenia and metabolic syndrome had higher odds of persistently low or rapidly declining cognition; metabolic syndrome alone showed no significant association. [1]
Automatic summary · not editorially reviewed
The key findings
The cohort included 5985 participants aged 45 years or more from the China Health and Retirement Longitudinal Study, 2011-2018. [1]
Co-occurring sarcopenia and metabolic syndrome was associated with 2.64-fold higher odds of the persistently low cognitive trajectory (95% CI 1.49-4.68). [1]
Metabolic syndrome alone showed no significant association with adverse cognitive trajectories after covariate adjustment. [1]
The source at a glance
- Study type / format
- Population-based observational cohort study (abstract)
- Population / context
- 5985 participants aged 45 years or more in the China Health and Retirement Longitudinal Study, 2011-2018.
- Summary based on
- Study abstract
- Original publication
- September 29, 2026
Cohort of 5985 Chinese adults aged 45+ followed 2011-2018
The study used data from the China Health and Retirement Longitudinal Study from 2011 to 2018. It included 5985 participants aged 45 years or more. The authors asked whether sarcopenia, metabolic syndrome, or both together were associated with adverse cognitive trajectories. They grouped participants by cognitive trajectory and compared groups, then explored which characteristics modified the associations. This was an observational cohort study, so it can show associations but not prove that either condition causes cognitive decline.
Supporting source [1]
Three cognitive trajectories; co-occurrence linked to two adverse ones
Three cognitive trajectories were identified: persistently high, persistently low, and rapidly declining. The authors describe persistently low function as possibly reflecting baseline vulnerability and rapid decline as prospective deterioration. In fully adjusted models, having both sarcopenia and metabolic syndrome was associated with 2.64-fold higher odds of the persistently low trajectory (95% confidence interval 1.49-4.68) and 2.38-fold higher odds of the rapidly declining trajectory (95% confidence interval 1.03-5.47). Sarcopenia alone was associated with higher odds of adverse cognitive outcomes, whereas metabolic syndrome alone showed no significant association. Age, body mass index and hemoglobin level were the strongest effect modifiers.
Supporting source [1]
Abstract-only scope; associations, not causes
This explainer is based on the abstract only; the full text was not reviewed. The abstract reports the cohort size, years and outcome categories, but not details such as how sarcopenia or metabolic syndrome were measured or how many participants fell into each trajectory. The reported odds ratios are associations from an observational cohort, not evidence that the co-occurrence causes cognitive decline. The authors call the co-occurrence a significant and modifiable risk factor; the abstract does not show that modifying it prevents cognitive decline.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Measurement details, trajectory group sizes and follow-up specifics are not reported in the abstract. Observational associations do not establish causation.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Chen Y, Ma K, Meng Z, Gao J, Feng X. · europepmc.org · September 29, 2026